Literature DB >> 26136941

Impact of the International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification of stage IA adenocarcinoma of the lung: Correlation between computed tomography images and EGFR and KRAS gene mutations.

Tengteng Wang1, Tao Zhang1, Xiaoxue Han2, X I Liu1, Naikang Zhou1, Yang Liu1.   

Abstract

The aim of the present study was to compare pathological diagnoses, as determined by the new International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society (IASLC/ATS/ERS) classification, with conventional radiological features. In addition, the present study aimed to evaluate the correlation among clinical characteristics, computed tomography (CT) images and gene mutation status in patients with stage IA adenocarcinoma of the lung. A total of 212 patients with stage IA lung adenocarcinoma were included in the study. The patients were classified into pure ground-glass opacity (pGGO), mixed GGO (mGGO) and solid GGO (sGGO) by CT imaging. Histological subtype was classified according to the IASLC/ATS/ERS classification of lung adenocarcinoma. In addition, epidermal growth factor receptor (EGFR) and Kirsten rat sarcoma (KRAS) mutation assays were performed, and 36.8% of patients (78/212) were determined to have an EGFR mutation, while 8.5% of patients (18/212) were found to have a KRAS mutation. According to the IASLC/ATS/ERS classification, 44 cases were diagnosed as adenocarcinoma in situ (AIS; 20.8%), 62 cases were diagnosed as minimally invasive adenocarcinoma (MIA; 29.2%) and 106 cases were classified as invasive adenocarcinoma (IAC; 50.0%). pGGO image patterns were observed in 39.2% of patients (n=83), while mGGO and sGGO patterns were observed in 28.8% (n=61) and 32.0% (n=68) of patients, respectively. From pGGO to sGGO, cases of AIS and MIA were shown to have a decreasing trend, while IAC cases exhibited an increasing trend (P=0.036). Analysis of the correlation between CT image patterns and gene mutations demonstrated that L858R point mutations, exon 19 deletions and KRAS mutations were more common in lesions with a lower GGO proportion (P=0.029, 0.027 and 0.018, respectively). Therefore, according to the IASLC/ATS/ERS classification, GGO imaging patterns were shown to correlate with subtypes of adenocarcinomas. In addition, EGFR and KRAS mutations were found to be associated with lesions with a low GGO proportion. Therefore, analysis of GGO lesions may offer useful indications of the histological subtype of an adenocarcinoma in patients with stage IA lung adenocarcinoma, and predictive value for EGFR and KRAS mutations.

Entities:  

Keywords:  gene mutation; ground-glass opacity; lung adenocarcinoma

Year:  2015        PMID: 26136941      PMCID: PMC4473664          DOI: 10.3892/etm.2015.2422

Source DB:  PubMed          Journal:  Exp Ther Med        ISSN: 1792-0981            Impact factor:   2.447


  48 in total

1.  Epidermal growth factor receptor mutation status in stage I lung adenocarcinoma with different image patterns.

Authors:  Kuo-Hsuan Hsu; Kun-Chieh Chen; Tsung-Ying Yang; Yi-Chen Yeh; Teh-Ying Chou; Hsuan-Yu Chen; Chi-Ren Tsai; Chih-Yi Chen; Chung-Ping Hsu; Jiun-Yi Hsia; Cheng-Yen Chuang; Ying-Huang Tsai; Kuan-Yu Chen; Ming-Shyan Huang; Wu-Chou Su; Yuh-Min Chen; Chao A Hsiung; Gee-Chen Chang; Chien-Jen Chen; Pan-Chyr Yang
Journal:  J Thorac Oncol       Date:  2011-06       Impact factor: 15.609

2.  The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies.

Authors:  Hongbin Ji; Danan Li; Liang Chen; Takeshi Shimamura; Susumu Kobayashi; Kate McNamara; Umar Mahmood; Albert Mitchell; Yangping Sun; Ruqayyah Al-Hashem; Lucian R Chirieac; Robert Padera; Roderick T Bronson; William Kim; Pasi A Jänne; Geoffrey I Shapiro; Daniel Tenen; Bruce E Johnson; Ralph Weissleder; Norman E Sharpless; Kwok-Kin Wong
Journal:  Cancer Cell       Date:  2006-05-25       Impact factor: 31.743

3.  NCCN Task Force report: Evaluating the clinical utility of tumor markers in oncology.

Authors:  Phillip G Febbo; Marc Ladanyi; Kenneth D Aldape; Angelo M De Marzo; M Elizabeth Hammond; Daniel F Hayes; A John Iafrate; R Kate Kelley; Guido Marcucci; Shuji Ogino; William Pao; Dennis C Sgroi; Marian L Birkeland
Journal:  J Natl Compr Canc Netw       Date:  2011-11       Impact factor: 11.908

4.  Clinicopathological characteristics of 11 NSCLC patients with EGFR-exon 20 mutations.

Authors:  Marius Lund-Iversen; Lilach Kleinberg; Lars Fjellbirkeland; Åslaug Helland; Odd Terje Brustugun
Journal:  J Thorac Oncol       Date:  2012-09       Impact factor: 15.609

5.  Early Lung Cancer Action Project: overall design and findings from baseline screening.

Authors:  C I Henschke; D I McCauley; D F Yankelevitz; D P Naidich; G McGuinness; O S Miettinen; D M Libby; M W Pasmantier; J Koizumi; N K Altorki; J P Smith
Journal:  Lancet       Date:  1999-07-10       Impact factor: 79.321

6.  Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer.

Authors:  Federico Cappuzzo; Fred R Hirsch; Elisa Rossi; Stefania Bartolini; Giovanni L Ceresoli; Lynne Bemis; Jerry Haney; Samir Witta; Kathleen Danenberg; Irene Domenichini; Vienna Ludovini; Elisabetta Magrini; Vanesa Gregorc; Claudio Doglioni; Angelo Sidoni; Maurizio Tonato; Wilbur A Franklin; Lucio Crino; Paul A Bunn; Marileila Varella-Garcia
Journal:  J Natl Cancer Inst       Date:  2005-05-04       Impact factor: 13.506

7.  CT findings and progression of small peripheral lung neoplasms having a replacement growth pattern.

Authors:  Shodayu Takashima; Yuichiro Maruyama; Minoru Hasegawa; Takeshi Yamanda; Takayuki Honda; Masumi Kadoya; Shusuke Sone
Journal:  AJR Am J Roentgenol       Date:  2003-03       Impact factor: 3.959

8.  Prognostic and predictive importance of p53 and RAS for adjuvant chemotherapy in non small-cell lung cancer.

Authors:  Ming-Sound Tsao; Sarit Aviel-Ronen; Keyue Ding; Davina Lau; Ni Liu; Akira Sakurada; Marlo Whitehead; Chang-Qi Zhu; Robert Livingston; David H Johnson; James Rigas; Lesley Seymour; Timothy Winton; Frances A Shepherd
Journal:  J Clin Oncol       Date:  2007-11-20       Impact factor: 44.544

9.  Introduction of the 7th edition eyelid carcinoma classification system from the American Joint Committee on Cancer-International Union Against Cancer staging manual.

Authors:  Darryl J Ainbinder; Bita Esmaeli; Stephen C Groo; Paul T Finger; Joseph P Brooks
Journal:  Arch Pathol Lab Med       Date:  2009-08       Impact factor: 5.534

10.  Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib.

Authors:  Gregory J Riely; William Pao; Duykhanh Pham; Allan R Li; Naiyer Rizvi; Ennapadam S Venkatraman; Maureen F Zakowski; Mark G Kris; Marc Ladanyi; Vincent A Miller
Journal:  Clin Cancer Res       Date:  2006-02-01       Impact factor: 12.531

View more
  14 in total

Review 1.  Pulmonary ground-glass opacity: computed tomography features, histopathology and molecular pathology.

Authors:  Jian-Wei Gao; Stefania Rizzo; Li-Hong Ma; Xiang-Yu Qiu; Arne Warth; Nobuhiko Seki; Mizue Hasegawa; Jia-Wei Zou; Qian Li; Marco Femia; Tang-Feng Lv; Yong Song
Journal:  Transl Lung Cancer Res       Date:  2017-02

2.  Lung Adenocarcinoma: Predictive Value of KRAS Mutation Status in Assessing Local Recurrence in Patients Undergoing Image-guided Ablation.

Authors:  Etay Ziv; Joseph P Erinjeri; Hooman Yarmohammadi; F Edward Boas; Elena N Petre; Song Gao; Waleed Shady; Constantinos T Sofocleous; David R Jones; Charles M Rudin; Stephen B Solomon
Journal:  Radiology       Date:  2016-07-19       Impact factor: 11.105

3.  [Computed tomography findings, clinicopathological features, genetic characteristics and prognosis of in situ and minimally invasive lung adenocarcinomas].

Authors:  Leilei Shen; Jixing Lin; Bailin Wang; Hengliang Xu; Kai Zhao; Lianbin Zhang
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2019-09-30

4.  Epidermal growth factor receptor mutation accelerates radiographic progression in lung adenocarcinoma presented as a solitary ground-glass opacity.

Authors:  Qijue Lu; Ye Ma; Zhao An; Tiejun Zhao; Zhiyun Xu; Hezhong Chen
Journal:  J Thorac Dis       Date:  2018-11       Impact factor: 2.895

5.  A Radiogenomics Ensemble to Predict EGFR and KRAS Mutations in NSCLC.

Authors:  Silvia Moreno; Mario Bonfante; Eduardo Zurek; Dmitry Cherezov; Dmitry Goldgof; Lawrence Hall; Matthew Schabath
Journal:  Tomography       Date:  2021-04-29

6.  Identification of Factors for the Preoperative Prediction of Tumour Subtype and Prognosis in Patients with T1 Lung Adenocarcinoma.

Authors:  Wang-Yu Zhu; Yong-Kui Zhang; Zhen-da Chai; Xiao-Fei Hu; Lin-Lin Tan; Zhao-Yu Wang; Zhi-Jun Chen; Han-Bo Le
Journal:  Dis Markers       Date:  2016-12-26       Impact factor: 3.434

7.  Survivin knockdown induces senescence in TTF‑1-expressing, KRAS-mutant lung adenocarcinomas.

Authors:  Toshiyuki Sumi; Sachie Hirai; Miki Yamaguchi; Yusuke Tanaka; Makoto Tada; Gen Yamada; Tadashi Hasegawa; Yohei Miyagi; Toshiro Niki; Atsushi Watanabe; Hiroki Takahashi; Yuji Sakuma
Journal:  Int J Oncol       Date:  2018-04-11       Impact factor: 5.650

8.  Associations between epidermal growth factor receptor mutations and histological subtypes of lung adenocarcinoma according to the IASLC/ATS/ERS classification in Chinese patients.

Authors:  Tengteng Wang; Yi Zhang; Baodong Liu; Mu Hu; Naikang Zhou; Xiuyi Zhi
Journal:  Thorac Cancer       Date:  2017-09-20       Impact factor: 3.500

Review 9.  [Overview of Clinical Progress in Pulmonary Ground-glass Nodules].

Authors:  Lei Li; Dan Liu; Yingying Zhu; Weimin Li
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2016-02

10.  Evaluation of dynamic image progression of minimally invasive and preinvasive lung adenocarcinomas.

Authors:  Tianxiang Chen; Xiaocheng Zhang; Alessio Campisi; Angelo Paolo Ciarrocchi; Andrea Dell'Amore; Liwei Song; Yunhai Yang; Chengshui Chen; Qingquan Luo
Journal:  Ann Transl Med       Date:  2021-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.